Non Small Cell Lung Cancer Clinical Trials in Nashville, Tennessee

51 studies are recruiting for non small cell lung cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

   The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: * What is the safe dose of KQB368 as a monotherapy? * Does KQB368 decrease the size of the tumor?…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   14 in total

   Run by

   Kumquat Biosciences Inc.

   See if you can join NCT07542704 on ClinicalTrials.gov

2. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

   This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   366 in total

   Run by

   BioNTech SE

   See if you can join NCT06712316 on ClinicalTrials.gov

3. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

   Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners - PPDS, Nashville, Tennessee

   Locations

   32 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT06043817 on ClinicalTrials.gov

4. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute - Nashville, Nashville, Tennessee

   Locations

   60 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

5. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

   The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Nashville, Tennessee

   Locations

   333 in total

   Run by

   AstraZeneca

   See if you can join NCT06692738 on ClinicalTrials.gov

6. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   17 in total

   Run by

   LigaChem Biosciences, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

7. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

   The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute-Nashville-48456, Nashville, Tennessee

   Locations

   85 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT04886804 on ClinicalTrials.gov

8. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

9. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

   This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   20 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07020221 on ClinicalTrials.gov

10. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    39 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

11. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult par…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    SCRI Oncology Partners /ID# 270162, Nashville, Tennessee

    Locations

    83 in total

    Run by

    AbbVie

    See if you can join NCT06568939 on ClinicalTrials.gov

12. A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    18 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT07154290 on ClinicalTrials.gov

13. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

    Stage

    Phase 2

    Ages

    18 to 95

    Site

    Research Site, Nashville, Tennessee

    Locations

    97 in total

    Run by

    AstraZeneca

    See if you can join NCT05061550 on ClinicalTrials.gov

14. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

15. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

    A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon and HCA Research Institute, Nashville, Tennessee

    Locations

    8 in total

    Run by

    EpiBiologics

    See if you can join NCT07462377 on ClinicalTrials.gov

16. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Tennessee Oncology - Nashville, Nashville, Tennessee

    Locations

    38 in total

    Run by

    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

17. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee

    Locations

    49 in total

    Run by

    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov

18. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Tennessee Oncology, Nashville, Tennessee

    Locations

    187 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

19. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    484 in total

    Run by

    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

20. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee

    Locations

    66 in total

    Run by

    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

21. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    SCRI Oncology Partners /ID# 276959, Nashville, Tennessee

    Locations

    117 in total

    Run by

    AbbVie

    See if you can join NCT07155187 on ClinicalTrials.gov

22. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

23. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

    Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    159 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT06765109 on ClinicalTrials.gov

24. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Nashville, Tennessee

    Locations

    20 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

25. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    SCRI Oncology Partners - Tennessee, Nashville, Tennessee

    Locations

    158 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06881784 on ClinicalTrials.gov